Literature DB >> 21613617

MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells.

Courtney L Erskine1, Christopher J Krco, Karen E Hedin, Nancy D Borson, Kimberly R Kalli, Marshall D Behrens, Sabrina M Heman-Ackah, Eric von Hofe, Peter J Wettstein, Mansour Mohamadzadeh, Keith L Knutson.   

Abstract

CD4 Th cells are critical to the development of coordinated immune responses to infections and tumors. Th cells are activated through interactions of the TCR with MHC class II complexed with peptide. T cell activation is dependent on the density of MHC peptide complexes as well as the duration of interaction of the TCR with APCs. In this study, we sought to determine whether MHC class II peptides could be modified with amino acid sequences that facilitated uptake and presentation with the goal of improving Th cell activation in vitro and in vivo. A model epitope derived from the murine folate receptor α, a self- and tumor Ag, was modified at its carboxyl terminus with the invariant chain-derived Ii-Key peptide and at its N terminus with a peptide that enhances uptake of Ag by APC. Modification of a peptide resulted in enhanced generation of high-avidity murine folate receptor α T cells that persisted in vivo and homed to sites of Ag deposition. The nesting approach was epitope and species independent and specifically excluded expansion of CD4 regulatory T cells. The resulting Th cells were therapeutic, enhanced in vivo helper activity and had an increased ability to resist tolerizing immune microenvironments. In addition to improved immunoadjuvants, this epitope modification strategy may be useful for enhancing ex vivo and in vivo generation of Th cells for preventing and treating diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21613617      PMCID: PMC3119756          DOI: 10.4049/jimmunol.1100658

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Short peptide sequences mimic HLA-DM functions.

Authors:  Chih-Ling Chou; Saied Mirshahidi; Katherine Wailen Su; AeRyon Kim; Kedar Narayan; Stanislav Khoruzhenko; Minzhen Xu; Scheherazade Sadegh-Nasseri
Journal:  Mol Immunol       Date:  2007-12-03       Impact factor: 4.407

2.  Allograft rejection mediated by memory T cells is resistant to regulation.

Authors:  Jaeseok Yang; Matthew O Brook; Manuela Carvalho-Gaspar; Jidong Zhang; Hilda E Ramon; Mohamed H Sayegh; Kathryn J Wood; Laurence A Turka; Nick D Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

3.  Antigen presentation by human microvascular endothelial cells triggers ICAM-1-dependent transendothelial protrusion by, and fractalkine-dependent transendothelial migration of, effector memory CD4+ T cells.

Authors:  Thomas D Manes; Jordan S Pober
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

4.  IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells.

Authors:  Thomas Korn; Meike Mitsdoerffer; Andrew L Croxford; Amit Awasthi; Valérie A Dardalhon; George Galileos; Patrick Vollmar; Gretta L Stritesky; Mark H Kaplan; Ari Waisman; Vijay K Kuchroo; Mohamed Oukka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-17       Impact factor: 11.205

Review 5.  Differentiation of effector CD4 T cell populations (*).

Authors:  Jinfang Zhu; Hidehiro Yamane; William E Paul
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

6.  Development of a novel chemokine-mediated in vivo T cell recruitment assay.

Authors:  Gabriele S V Campanella; Benjamin D Medoff; Lindsay A Manice; Richard A Colvin; Andrew D Luster
Journal:  J Immunol Methods       Date:  2008-01-09       Impact factor: 2.303

7.  The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity.

Authors:  Marshall D Behrens; Wolfgang M Wagner; Christopher J Krco; Courtney L Erskine; Kimberly R Kalli; James Krempski; Ekram A Gad; Mary L Disis; Keith L Knutson
Journal:  Blood       Date:  2007-11-20       Impact factor: 22.113

8.  Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.

Authors:  Jarrod P Holmes; Linda C Benavides; Jeremy D Gates; Mark G Carmichael; Matthew T Hueman; Elizabeth A Mittendorf; James L Murray; Asna Amin; Dianna Craig; Eric von Hofe; Sathibalan Ponniah; George E Peoples
Journal:  J Clin Oncol       Date:  2008-07-10       Impact factor: 44.544

Review 9.  Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease.

Authors:  S Q Crome; A Y Wang; M K Levings
Journal:  Clin Exp Immunol       Date:  2009-11-11       Impact factor: 4.330

10.  The application of real-time PCR to the analysis of T cell repertoires.

Authors:  Peter Wettstein; Michael Strausbauch; Terry Therneau; Nancy Borson
Journal:  Nucleic Acids Res       Date:  2008-10-03       Impact factor: 16.971

View more
  6 in total

Review 1.  Ebola Vaccine: How Far are we?

Authors:  Rajani Sharma; Ketki Jangid
Journal:  J Clin Diagn Res       Date:  2017-05-01

2.  Chimeric Newcastle Disease Virus-like Particles Containing DC-Binding Peptide-Fused Haemagglutinin Protect Chickens from Virulent Newcastle Disease Virus and H9N2 Avian Influenza Virus Challenge.

Authors:  Xiaohong Xu; Jing Qian; Lingsong Qin; Jindou Li; Cong Xue; Jiaxin Ding; Weiqi Wang; Wei Ding; Renfu Yin; Ningyi Jin; Zhuang Ding
Journal:  Virol Sin       Date:  2020-04-09       Impact factor: 4.327

Review 3.  New generation of oral mucosal vaccines targeting dendritic cells.

Authors:  Jennifer L Owen; Bikash Sahay; Mansour Mohamadzadeh
Journal:  Curr Opin Chem Biol       Date:  2013-07-05       Impact factor: 8.822

Review 4.  Activation of B cells by a dendritic cell-targeted oral vaccine.

Authors:  Bikash Sahay; Jennifer L Owen; Tao Yang; Mojgan Zadeh; Yaima L Lightfoot; Jun-Wei Ge; Mansour Mohamadzadeh
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

5.  Recombinant house dust mite allergens.

Authors:  Susanne Vrtala; Hans Huber; Wayne R Thomas
Journal:  Methods       Date:  2013-07-31       Impact factor: 3.608

6.  Colonic immune stimulation by targeted oral vaccine.

Authors:  Mahesh Kathania; Mojgan Zadeh; Yaíma L Lightfoot; Robert M Roman; Bikash Sahay; Jeffrey R Abbott; Mansour Mohamadzadeh
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.